pharmabiz.com The incidence and severity of Chemotherapy Induced Diarrhoea (CID) varies considerably with the nature and dose of the cytotoxic therapy, with regimens containing Irinotecan and 5-fluorouracil (5-FU) being associated with rates as high as 80 per cent.
Wall Street Journal (press release) The incidence and severity of Chemotherapy Induced Diarrhea (CID) varies considerably with the nature and dose of the cytotoxic therapy, with regimens containing Irinotecan and 5-fluorouracil (5-FU) being associated with rates as high as 80%. Current ... and more »
The Herald | HeraldOnline.com Pexa-Vec is also being evaluated in a phase 1/2 clinical trial in patients with treatment-refractory colorectal cancer as monotherapy and in combination with irinotecan , and in a phase 2a clinical trial in treatment-refractory kidney cancer patients ... and more »
Business Wire (press release) Pexa-Vec is also being evaluated in a phase 1/2 clinical trial in patients with treatment-refractory colorectal cancer as monotherapy and in combination with irinotecan , and in a Phase 2a clinical trial in treatment-refractory kidney cancer patients ... and more »
Marketwire (press release) Pexa-Vec is also being evaluated in a Phase 1-2 clinical study in patients with treatment-refractory colorectal cancer as monotherapy and in combination with irinotecan , and in a Phase 2a clinical study in treatment-refractory kidney cancer patients ... and more »
